Daclizumab
Relapsing-Remitting Multiple Sclerosis
Explore 71 assets in Relapsing-Remitting Multiple Sclerosis →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Biogen
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02881567CT.gov Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab | — | Terminated | — | — | — |
NCT01797965CT.gov Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | — | Terminated | — | — | — |
NCT01462318CT.gov An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT01064401CT.gov Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT01051349CT.gov Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT00870740CT.gov Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT00390221CT.gov Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT00071838CT.gov Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Relapsing-Remitting Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Daclizumab (this asset) | Biogen | P3 | BB · 68 |
| Natalizumab | Biogen | P4 | BBB |
| Glatiramer | University Hospital, Montpellier | P4 | BBB |
| Fingolimod | TG Therapeutics, Inc. | P4 | BBB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Biogen | P4 | BBB |
| 2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER | University Hospital, Montpellier | P4 | BBB |
| Cladribine | Uppsala University | P4 | BBB |
| Ocrelizumab | Biocad | P4 | BBB |
| Phytonadione, (E)-(±)- | Biogen | P4 | BBB |
+42 more in the Relapsing-Remitting Multiple Sclerosis cohort
Other indications for Daclizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Leukemia | — | P2 | B · 58 |
| Lymphoma | — | P2 | B · 58 |
| Plasma Cell Myeloma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Daclizumab in Relapsing-Remitting Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/daclizumab-relapsing-remitting-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →